BioXcel Therapeutics recently reported its Q1 2026 results alongside submission of a supplemental NDA to expand IGALMI’s label for at-home treatment of agitation. The company’s AI-powered drug repurposing platform underpins its neuroscience and immuno-oncology pipeline, with the FDA-approved IGALMI as the commercial anchor. Despite successful clinical milestones, BioXcel faces significant liquidity and debt pressures, maintaining a strategic focus on neuroscience assets while deprioritizing immuno-oncology development. Execution risks center on regulatory approvals, market acceptance, operational cash burn, and dependency on third parties.